Erin Weeda to Pulmonary Embolism
This is a "connection" page, showing publications Erin Weeda has written about Pulmonary Embolism.
Connection Strength
5.468
-
Saddle pulmonary embolism and in-hospital mortality in patients with cancer. Int J Clin Oncol. 2019 Jun; 24(6):727-730.
Score: 0.522
-
Comorbid cancer and use of thrombolysis in acute pulmonary embolism. J Thromb Thrombolysis. 2019 Feb; 47(2):324-327.
Score: 0.521
-
External validation of three risk stratification rules in patients presenting with pulmonary embolism and cancer. Support Care Cancer. 2019 Mar; 27(3):921-925.
Score: 0.504
-
External Validation of Generic and Cancer-Specific Risk Stratification Tools in Patients With Pulmonary Embolism and Active Cancer. J Natl Compr Canc Netw. 2017 12; 15(12):1476-1482.
Score: 0.481
-
Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status. Int J Clin Pract. 2017 Jan; 71(1).
Score: 0.451
-
Outcomes associated with observation stays versus inpatient admissions for pulmonary embolism. J Thromb Thrombolysis. 2016 Nov; 42(4):513-9.
Score: 0.446
-
Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin. Intern Emerg Med. 2017 Apr; 12(3):311-318.
Score: 0.445
-
Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism. Pharmacotherapy. 2016 10; 36(10):1109-1115.
Score: 0.442
-
Outcomes associated with observation status versus inpatient management of pulmonary embolism patients anticoagulated with rivaroxaban. Int J Cardiol. 2016 Nov 01; 222:846-849.
Score: 0.439
-
External Validation of the Hestia Criteria for Identifying Acute Pulmonary Embolism Patients at Low Risk of Early Mortality. Clin Appl Thromb Hemost. 2017 Oct; 23(7):769-774.
Score: 0.433
-
Clinical prediction rules for mortality in patients with pulmonary embolism and cancer to guide outpatient management: a meta-analysis. J Thromb Haemost. 2018 02; 16(2):279-292.
Score: 0.121
-
Observation management of pulmonary embolism and agreement with claims-based and clinical risk stratification criteria in United States patients: a retrospective analysis. BMC Pulm Med. 2017 Feb 13; 17(1):37.
Score: 0.114
-
External validation of a claims-based and clinical approach for predicting post-pulmonary embolism outcomes among United States veterans. Intern Emerg Med. 2017 Aug; 12(5):613-619.
Score: 0.114
-
External validation of a multivariable claims-based rule for predicting in-hospital mortality and 30-day post-pulmonary embolism complications. BMC Health Serv Res. 2016 10 22; 16(1):610.
Score: 0.111
-
Is Rivaroxaban Associated With Shorter Hospital Stays and Reduced Costs Versus Parenteral Bridging to Warfarin Among Patients With Pulmonary Embolism? Clin Appl Thromb Hemost. 2017 Oct; 23(7):830-837.
Score: 0.110
-
Outcomes related to variation in hospital pulmonary embolus observation stay utilization. Hosp Pract (1995). 2016 Aug; 44(3):133-7.
Score: 0.108
-
Effect of vital sign measurement timing on Pulmonary Embolism Severity Index (PESI) and simplified PESI 30-day mortality risk determination. Thromb Res. 2016 May; 141:8-10.
Score: 0.106